Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
IPO Year:
Exchange: NASDAQ
Website: https://www.embecta.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $13.00 → $20.00 | Underweight → Equal-Weight | Morgan Stanley |
| 11/27/2024 | $26.00 | Neutral → Buy | BTIG Research |
| 10/20/2023 | Peer Perform | Wolfe Research | |
| 1/6/2023 | $28.00 | Equal-Weight → Underweight | Morgan Stanley |
| 9/8/2022 | Neutral | BTIG Research | |
| 8/1/2022 | $33.00 | Equal-Weight | Morgan Stanley |
| 6/21/2022 | $25.00 | Underperform | BofA Securities |
4 - Embecta Corp. (0001872789) (Issuer)
DEFA14A - Embecta Corp. (0001872789) (Filer)
DEF 14A - Embecta Corp. (0001872789) (Filer)
10-K - Embecta Corp. (0001872789) (Filer)
8-K - Embecta Corp. (0001872789) (Filer)
NT 10-K - Embecta Corp. (0001872789) (Filer)
8-K - Embecta Corp. (0001872789) (Filer)
8-K - Embecta Corp. (0001872789) (Filer)
10-Q - Embecta Corp. (0001872789) (Filer)
8-K - Embecta Corp. (0001872789) (Filer)
SD - Embecta Corp. (0001872789) (Filer)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SC 13G - Embecta Corp. (0001872789) (Subject)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SC 13G - Embecta Corp. (0001872789) (Subject)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SC 13G - Embecta Corp. (0001872789) (Subject)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024. "We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics. We continued to execute on our strategic priorities, and to date, our significant accomplishments include the successful transition of approximately 98% of our revenue to our own ERP system, shared service capabilities, and distribution infrastructure, with India remaining as o
PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2024 to stockholders of record at the close of business on December 6, 2024. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 26, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Thursday, November 26, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET
PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2024. "During the third quarter our business performed in alignment with our expectations. We generated strong gross, operating and EBITDA margins even as revenue was impacted by the expected timing of customer orders that had positively impacted our second quarter results," said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. "From a year-to-date perspective, our financial results demonstrated the contin
PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024 to stockholders of record at the close of business on August 27, 2024. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels
PARSIPPANY, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal third quarter 2024 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, Aug 9, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on Aug 9, 2024, via the embecta investor rela
PARSIPPANY, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2024. "Our performance in the second quarter and fiscal first half of 2024 underscores the resiliency of our base business, as well as strong operational execution by our global team. Since our spinoff approximately two years ago, we've remained steadfast in delivering on our financial and strategic priorities, including standing embecta up as an independent company; maintaining stability within our core injection business; and investing in growth, most notably beh
PARSIPPANY, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 14, 2024 to stockholders of record at the close of business on May 28, 2024. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships, and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channe
PARSIPPANY, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal second quarter 2024 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, May 9, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on May 9, 2024, via the embecta inves
PARSIPPANY, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (NASDAQ:EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 7:30 a.m. PT / 10:30 a.m. ET. Audio webcasts of the presentations will be accessible under the "News & Events" section of the Company's investor relations website at investors.embecta.com. About embecta embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the
PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024. "We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics. We continued to execute on our strategic priorities, and to date, our significant accomplishments include the successful transition of approximately 98% of our revenue to our own ERP system, shared service capabilities, and distribution infrastructure, with India remaining as o
PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2024 to stockholders of record at the close of business on December 6, 2024. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 26, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Thursday, November 26, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET
While 9 out of 10 people with diabetes are living with T2D, many of the automated insulin delivery solutions currently on the market were designed for people living with T1D.300-unit insulin reservoir is more suitable for people with T2D who are interested in moving from multiple daily injections (MDI) to pump therapy, based on an average daily dose of 95.9 units of insulin.1 PARSIPPANY, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery sys
PARSIPPANY, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that management will participate in the following investor events: 2024 Wells Fargo Healthcare Conference • Management will host one-on-one investor meetings on Wednesday, September 4, 2024, at the Encore Boston Harbor Hotel in Boston. 2024 Morgan Stanley 22nd Annual Global Healthcare Conference • Management will host a fireside session on Thursday, September 5, 2024, at 2:35 p.m. Eastern Time (ET) at the Marriott Marquis in New York. Audio webcasts of the presentations will be accessible under the "News & E
PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2024. "During the third quarter our business performed in alignment with our expectations. We generated strong gross, operating and EBITDA margins even as revenue was impacted by the expected timing of customer orders that had positively impacted our second quarter results," said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. "From a year-to-date perspective, our financial results demonstrated the contin
PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024 to stockholders of record at the close of business on August 27, 2024. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels
Genpact's deep domain knowledge and data expertise enables embecta's vision to make a meaningful impact in the healthcare sector NEW YORK, July 29, 2024 /PRNewswire/ -- Genpact (NYSE:G), a global professional services and solutions firm delivering outcomes that shape the future, has been working with embecta (NASDAQ:EMBC), a global diabetes care company, to support its spin-off from Becton Dickinson and Company (BD) and subsequent evolution as an independent leader in the diabetes technology market. "Genpact's deep expertise in the life sciences and healthcare sectors enables
4 - Embecta Corp. (0001872789) (Issuer)
3 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
3/A - Embecta Corp. (0001872789) (Issuer)
Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously
BTIG Research upgraded Embecta Corp. from Neutral to Buy and set a new price target of $26.00
Wolfe Research initiated coverage of Embecta Corp. with a rating of Peer Perform
Morgan Stanley downgraded Embecta Corp. from Equal-Weight to Underweight and set a new price target of $28.00
BTIG Research initiated coverage of Embecta Corp. with a rating of Neutral
Morgan Stanley initiated coverage of Embecta Corp. with a rating of Equal-Weight and set a new price target of $33.00
BofA Securities initiated coverage of Embecta Corp. with a rating of Underperform and set a new price target of $25.00
WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the
Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply
PARSIPPANY, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company, announced it will ring the Nasdaq opening bell today, in recognition of National Diabetes Awareness Month in November. The coming year is also a time to celebrate the company's heritage in providing solutions to people living with diabetes, including 100 years since the development and launch of the first syringe dedicated to insulin delivery. Advocacy and professional groups including the Association of Diabetes Care & Education Specialists (ADCES), Beyond Type 1, Beyond Type 2, Camp Nejeda, Children with Diabetes, Diabetes Education and Camping Association (DECA),
Campbell Soup Company (NYSE:CPB) today announced the appointment of Carrie L. Anderson as Executive Vice President and Chief Financial Officer, effective Feb. 6. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005725/en/Carrie Anderson (Photo: Business Wire) Anderson will lead Campbell's finance function, including controllership, corporate financial planning and analysis, corporate strategy and development, tax, treasury, internal audit, investor relations, transactional services and financial systems. She will report to Campbell's President and Chief Executive Officer Mark Clouse and become a member of the company's Operat
Nordson Corporation (NASDAQ:NDSN) announced the appointment of Dr. Milton Morris, recently retired president and chief executive officer of Neuspera Medical, Inc., to its board of directors. Dr. Morris will bring robust business leadership experience, as well as a legacy of successful product innovation, to the board. "We are pleased to welcome Milton as a new independent director. His passion for innovation and new product development aligns well with Nordson's strength of understanding customer needs and bringing diversified precision technology solutions to market. In addition, his professional background in medical devices will enhance our understanding, as Nordson plans to further exp